28. RELATED PARTY TRANSACTIONS

The principal related party relationships requiring disclosure in the consolidated financial statements of the Group under IAS 24 Related Party Disclosures pertain to the existence of subsidiary undertakings and equity accounted investments, transactions entered into by the Group with these subsidiary undertakings and equity accounted investments and the identification and compensation of and transactions with key management personnel.

(a) Group

Transactions

Transactions between the Group and its related parties are made on terms equivalent to those that prevail in arm’s length transactions.

Subsidiary undertakings

The consolidated financial statements include the financial statements of the Company and its subsidiaries. A listing of all subsidiaries is provided in note 29. Sales to and purchases from subsidiary undertakings, together with outstanding payables and receivables, are eliminated in the preparation of the consolidated financial statements in accordance with IFRS 10 Consolidated Financial Statements.

Equity accounted investments

See note 13 for details on equity accounted investments.

Loans extended by the Group to equity accounted investments are considered trading in nature and are included within advances to customers in trade & other receivables (note 15).

Details of transactions with equity accounted investments during the year and related outstanding balances at the year end are as follows:

Joint ventures

Associates

2022

2021

2022

2021

€m

€m

€m

€m

Net revenue

1.3

0.9

0.5

0.1

Trade & other receivables

0.5

0.2

-

-

Purchases

0.9

0.3

0.5

0.2

Trade & other payables

0.1

-

-

-

Loans

1.5

1.5

0.9

1.0

All outstanding trading balances with equity accounted investments, which arose from arm’s length transactions, are to be settled in cash within 60 days of the reporting date.

Key management personnel

For the purposes of the disclosure requirements of IAS 24 Related Party Disclosures, the Group has defined the term ‘key management personnel’, as its Executive and Non-Executive Directors. Executive Directors participate in the Group’s equity share award schemes (note 4) and are covered for death in service by an insurance policy. Executive Directors may also benefit from medical insurance under a Group policy (or the Group offers a cash alternative). No other non-cash benefits are provided. Non-Executive Directors do not receive share-based payments nor post-employment benefits.

Details of key management remuneration, charged to the Income Statement, are as follows:

2022

2021

Number

Number

Number of individuals

10

10

€m

€m

Salaries and other short-term employee benefits

2.3

1.9

Post-employment benefits

0.1

0.2

Equity settled share-based payment charge/(credit) and related dividend accrual

1.7

(0.7)

Pay in lieu of notice

-

0.6

Total

4.1

2.0

During the current and prior financial year, there were no transactions or balances between the Group and its key management personnel or members of their close family apart from:

  • The Group sells stock to Tesco plc, of which Stewart Gilliland is a Non-Executive Director;
  • The Group purchases from and sells stock to St Austell Brewery Company Limited, of which Jill Caseberry is a Non-Executive Director; and
  • Also in the current financial year, the Group sold and purchased stock from Britvic plc, of which Emer Finnan is a Non-Executive Director.

All transactions with related parties involve the normal supply of goods or services and are priced on an arm’s length basis.

For the purposes of the Section 305 of the Companies Act 2014, the aggregate gains by Directors on the exercise of share options during FY2022 was €nil (FY2021: €0.6m).

(b) Company

The Company has a related party relationship with its subsidiary undertakings. Details of the transactions in the year between the Company and its subsidiary undertakings are as follows:

2022

2021

€m

€m

Dividend income

-

76.6

Expenses paid on behalf of and recharged by subsidiary undertakings to the Company

(2.8)

(2.1)

Equity settled share-based payments for employees of subsidiary undertakings

1.5

0.8

(Injection)/drawdown of cash funding and other movements with subsidiary undertakings

(16.9)

49.3